Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin)

International Journal of Oncology

Volumn 37, Issue 3, 2010, Pages 669-678

  Oliveras Ferraros, Cristina ^a   Vazquez Martin, Alejandro ^a   Martin Castillo, Begoña ^a   Pérez Martínez, Maria Carmen ^a   Cufí, Silvia ^a   Del Barco, Sonia ^a   Bernado, Luis ^a   Brunet, Joan ^a   López Bonet, Eugeni ^a   Menendez, Javíer A ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Basal like; HER2; Insulin like growth factor; Proteomics; Trastuzumab

Indexed keywords

AMPHIREGULIN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEUROTROPHIN; PLATELET DERIVED GROWTH FACTOR AA; PROTEIN P53; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOGENESIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTRADUCTAL CARCINOMA; LYMPHOCYTIC INFILTRATION; MITOSIS INDEX; NECROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEOMICS; SIGNAL TRANSDUCTION; SQUAMOUS CELL METAPLASIA; TUMOR CELL; TUMOR DIFFERENTIATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOPHENOTYPING; PROTEOMICS; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; TUMOR MARKERS, BIOLOGICAL;

EID: 77956519036     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000716     Document Type: Article

References (41)

1. Nahta R and Esteva FJ: HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9: 5078-5084, 2003. (Pubitemid 37413555)
2. Nahta R and Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138, 2006.
3. Nahta R, Yu D, Hung MC, Hortobagyi GN and Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280, 2006.
4. Nahta R and Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene 26: 3637-3643, 2007.
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
6. Valabrega G, Montemurro F and Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977-984, 2007.
7. Nahta R and Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215, 2006. (Pubitemid 44804004)
8. Chen FL, Xia W and Spector NL: Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 14: 6730-6734, 2008.
9. Spector NL and Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27: 5838-5847, 2009.
10. Esteva FJ, Yu D, Hung MC and Hortobagyi GN: Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7: 98-107, 2010.
11. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K and Isola J: Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3: 1585-1592, 2004.
12. Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J and Jovin TM: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473-482, 2005.
13. Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J and Nagy P: Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 43: 2423-2433, 2007.
14. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD and Winer EP: Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13: 1198-1207, 2007.
15. Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S and Abdulkarim B: Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 69: 8620-8628, 2009.
16. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
17. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
18. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL and Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
19. Rakha EA, Reis-Filho JS and Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol 26 :2568-2581, 2008.
20. Fadare O and Tavassoli FA: Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol 5: 149-159, 2008. (Pubitemid 351330667)
21. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J and Isola J: Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12: 4185-4191, 2006.
22. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT and Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271, 2006.
23. Jönsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringnér M, Höglund M and Borg A: High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46: 543-558, 2007.
24. Liu H, Fan Q, Zhang Z, Li X, Yu H and Meng F: Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 39: 167-174, 2008.
25. Yehiely F, Moyano JV, Evans JR, Nielsen TO and Cryns VL: Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12: 537-544, 2006. (Pubitemid 44740239)
26. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997, 2008.
27. Bedard PL, Cardoso F and Piccart-Gebhart MJ: Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 14: 55-66, 2009.
28. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN and Bacus SS: The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91: 1190-1194, 2004.
29. Menendez JA and Lupu R: Transphosphorylation of kinasedead HER3 and breast cancer progression: a new standpoint or an old concept revisited? Breast Cancer Res 9: 111, 2007.
30. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) induced changes in the expression and nucleocytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20: 3-10, 2007.
31. Motoyama AB, Hynes NE and Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151-3158, 2002.
32. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA and Arteaga CL: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919, 2007.
33. Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, Hemmilä P, Ilvesaro J and Isola J: Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294: 211-219, 2010.
34. Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, Moseley MA 3rd, Thompson JW, Chen FL, Koch KM and Spector NL: Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther 9: 292-299, 2010.
35. Mañes S, Mira E, Gómez-Mouton C, Zhao ZJ, Lacalle RA and Martínez-A C: Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol 19: 3125-3135, 1999. (Pubitemid 29144557)
36. Zhang X, Lin M, van Golen KL, Yoshioka K, Itoh K and Yee D: Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. Breast Cancer Res Treat 93: 159-168, 2005.
37. Guvakova MA: Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol 39: 890-909, 2007.
38. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM and Hochwald SN: FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29: 1096-1107, 2008.
39. Yokotsuka M, Iwaya K, Saito T, Pandiella A, Tsuboi R, Kohno N, Matsubara O and Mukai K: Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer. Breast Cancer Res Treat, Apr 24, 2010 (E-pub ahead of print).
40. Huang D, Khoe M, Befekadu M, Chung S, Takata Y, Ilic D and Bryer-Ash M: Focal adhesion kinase mediates cell survival via NF-kappaB and ERK signaling pathways. Am J Physiol Cell Physiol 292: C1339-C1352, 2007.
41. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE and Hemler ME: Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70: 2256-2263, 2010.